Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	13.69	14.04	12.61	11.31	8	10.62
Research & Development	17.57	17.33	15.08	9.21	6.61	6.65
Operating Expenses	31.26	31.38	27.69	20.52	14.61	17.27
Operating Income	-31.26	-31.38	-27.69	-20.52	-14.61	-17.27
Interest & Investment Income	4.63	4.34	0.88	0.01	-	-
Other Non Operating Income (Expenses)	-0.07	-0.07	-0.15	-0.09	-3.22	0.03
EBT Excluding Unusual Items	-26.7	-27.1	-26.96	-20.61	-17.83	-17.24
Gain (Loss) on Sale of Investments	-2.99	-2.99	-	-	-	-
Pretax Income	-29.69	-30.09	-26.96	-20.61	-17.83	-17.24
Earnings From Continuing Operations	-29.69	-30.09	-26.96	-20.61	-17.83	-17.24
Net Income	-29.69	-30.09	-26.96	-20.61	-17.83	-17.24
Preferred Dividends & Other Adjustments	-	-	-	-	4.5	-
Net Income to Common	-29.69	-30.09	-26.96	-20.61	-22.33	-17.24
Shares Outstanding (Basic)	126	126	127	117	11	8
Shares Outstanding (Diluted)	126	126	127	117	11	8
Shares Change (YoY)	-0.69%	-0.43%	8.27%	934.13%	33.09%	104.36%
EPS (Basic)	-0.24	-0.24	-0.21	-0.18	-1.97	-2.03
EPS (Diluted)	-0.24	-0.24	-0.21	-0.18	-1.97	-2.03
Free Cash Flow	-18.64	-20.96	-20.79	-16.48	-11.58	-9.14
Free Cash Flow Per Share	-0.15	-0.17	-0.16	-0.14	-1.02	-1.08
EBITDA	-31.23	-31.35	-27.68	-20.5	-14.56	-17.21
D&A For EBITDA	0.03	0.02	0.01	0.02	0.05	0.05
EBIT	-31.26	-31.38	-27.69	-20.52	-14.61	-17.27

Source: S&P Capital IQ. Standard template.